CMS CRUSH Rule: Fraud Oversight and Psychedelic Medicine Access
The proposed CRUSH rule from CMS brings new compliance demands for all providers, signaling increased scrutiny that could shape reimbursement and access for psychedelic-assisted therapies.
CMS Proposes CRUSH Rule to Intensify Fraud Oversight
The Centers for Medicare & Medicaid Services (CMS) published the proposed CRUSH rule on November 19, 2026, aiming to strengthen fraud detection and program integrity across Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and Marketplace health coverage. The rule, officially titled "Medicare, Medicaid, and Marketplace Programs; Comprehensive Regulations To Uncover Suspicious Healthcare (CRUSH)," would revise provider enrollment, medical review, and investigative procedures to maximize the agency's regulatory authority and address inappropriate payments. (Federal Register: 2026-23461)
Mechanism: Provider Enrollment, Billing, and Compliance Under CRUSH
The CRUSH rule proposes enhanced verification of provider credentials, expanded data analytics for billing patterns, and stricter oversight of provider enrollment and revalidation. For psychedelic medicine providers—including clinics, clinical trial sites, and research entities—these mechanisms mean more rigorous scrutiny of billing practices, clinical documentation, and compliance with federal program requirements. The rule's language does not single out psychedelic therapies, but any provider seeking reimbursement or participation in federal programs will be subject to the new standards.
- Provider enrollment: New and existing providers may face additional background checks and periodic revalidation.
- Billing review: Claims for emerging therapies, such as psychedelic-assisted psychotherapy, could trigger audits if they deviate from established norms.
- Data analytics: CMS will use advanced analytics to flag suspicious billing, which may disproportionately affect novel or less-understood interventions.
A non-obvious implication is that clinics piloting psychedelic therapies under expanded access or off-label use could encounter administrative delays or denials, even when acting in good faith, due to the lack of established billing codes or precedents for these treatments.
Policy and Research Implications for Psychedelic Medicine
The CRUSH rule's broad approach to fraud detection could shape the landscape for psychedelic-assisted therapies if and when they become covered benefits. As clinical trials progress and some psychedelic treatments approach regulatory approval, providers may seek reimbursement through Medicare, Medicaid, or Marketplace plans. The heightened compliance environment will require robust documentation, clear protocols, and proactive engagement with CMS guidance.
For researchers, the rule underscores the importance of aligning trial design and reporting with federal billing and compliance expectations. Failure to anticipate these requirements could jeopardize future reimbursement or participation in federal programs, potentially slowing adoption or limiting patient access.
Risks, Unknowns, and Real-World Failure Modes
The primary risk for psychedelic medicine providers is inadvertent non-compliance, which can result in payment denials, audits, or exclusion from federal programs. The lack of established billing codes for many psychedelic interventions introduces ambiguity, raising the risk of claims being flagged as suspicious. Additionally, clinics operating at the intersection of research and clinical care may face unique challenges in delineating billable services versus experimental interventions.
One real-world failure mode is the "compliance gap"—where providers, unfamiliar with evolving CMS requirements, submit claims that do not meet new documentation or coding standards. This can lead to retroactive recoupments or legal exposure, even absent intent to defraud. Another concern is the potential chilling effect: some providers may opt out of offering psychedelic therapies to federally insured patients due to perceived compliance risks, limiting access for vulnerable populations.
Looking Ahead: Preparing for a Stricter Compliance Environment
Psychedelic medicine stakeholders should anticipate a more stringent regulatory climate as CMS implements the CRUSH rule. Proactive steps—such as investing in compliance infrastructure, engaging with CMS on coding and documentation standards, and participating in provider education—will be critical for clinics and research sites. As the field evolves, collaboration between regulators, providers, and researchers will shape not only access but also the integrity and sustainability of psychedelic-assisted care within federal health programs.
By Dr. Alex M. Carter, JD, PhD. Reviewed by Dr. Alex M. Carter on 2026-11-20. All regulatory citations and policy analysis are based on direct review of the official Federal Register notice and CMS primary sources.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.